Scott Kopetz, MD, PhD, on the Results of the SWOG S1406 Trial

January 15, 2021
Hannah Slater

SWOG S1406 evaluated the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E-mutated metastatic colorectal cancer who had been previously treated with 1 or 2 regimens.

Results from the randomized SWOG S1406 trial (NCT02164916) indicated that simultaneous use of an EGFR plus a BRAF inhibitor combined with irinotecan was found to be effective in BRAF V600E–mutated colorectal cancer (CRC).1

The first cooperative group study in CRC to prospectively assess a molecular biomarker addressing a small patient subset, SWOG S1406 evaluated the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E­–mutated metastatic CRC who had been previously treated with 1 or 2 regimens.

The study, published in the Journal of Clinical Oncology, was led by Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center.2 In an interview with CancerNetwork®, Kopetz discussed the results of the study and what they may offer patients with BRAF V600E­–mutated metastatic CRC.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences channels.

References:

1. Kopetz S, Guthrie KA, Morris VK, et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).J Clin Oncol. Published online December 23, 2020. doi: 10.1200/JCO.20.01994

2. Triple Chemo Combo Improves CRC Outcomes. News release. Published December 23, 2020. Accessed January 11, 2021. https://www.swog.org/news-events/news/2020/12/23/triple-chemo-combo-improves-crc-outcomes